Genmab A (GMAB) Depreciation & Amortization (CF) (2024 - 2026)

Genmab A (GMAB) has reported Depreciation & Amortization (CF) for 3 consecutive years, with $12.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Depreciation & Amortization (CF) rose 71.43% year-over-year to $12.0 million; the trailing twelve-month figure through Jun 2026 stood at $36.0 million (up 100.0% YoY), and the FY2025 full-year result was $16.0 million, up 45.45% from the prior year.
• Depreciation & Amortization (CF) eased to $12.0 million in Q2 2026 per GMAB's latest filing, from $13.0 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $13.0 million in Q1 2026 and bottomed at $2.0 million in Q1 2024.
• Historically, Depreciation & Amortization (CF) has averaged $7.5 million across 3 years, with a median of $7.0 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization (CF) surged 57.14% in 2025, then surged 225.0% in 2026.
• Over 3 years, Depreciation & Amortization (CF) stood at $7.0 million in 2024, then soared by 57.14% to $11.0 million in 2025, then gained by 9.09% to $12.0 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $12.0 million, $13.0 million, and $11.0 million for Q2 2026, Q1 2026, and Q3 2025 respectively.